CASP3 and cancer: (1) Cell viability and morphological examination assays showed that as compared with single agents, combination treatment caused more cancer cell losing viability; (2) Western blotting analysis showed that SM-164 markedly augmented Doxorubicin-mediated PARP cleavage and caspase-3 activation, two key biomarkers for apoptosis induction.